Metabolic syndrome and systemic lupus erythematosus: the connection

References

• Cameron A. The metabolic syndrome: validity and utility of clinical definitions for cardiovascular disease and diabetes risk prediction. Maturitas. 2010;65:117–121.
   PubMed Web of Science ®Google Scholar
• Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683–689.
   PubMed Web of Science ®Google Scholar
• Alexander CM, Landsman PB, Teutsch SM, et al. Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52:1210–1214.
   PubMed Web of Science ®Google Scholar
• Wong ND, Nelson JC, Granston T, et al. Metabolic syndrome, diabetes, and incidence and progression of coronary calcium: the Multiethnic Study of Atherosclerosis study. JACC Cardiovasc Imaging. 2012;5:358–366.
   PubMed Web of Science ®Google Scholar
• Thomas GN, Schooling CM, McGhee SM, et al. Hong Kong cardiovascular risk factor prevalence study steering committee. Metabolic syndrome increases all-cause and vascular mortality: the Hong Kong Cardiovascular Risk Factor Study. Clin Endocrinol (Oxf). 2007;66:666–671.
   PubMed Web of Science ®Google Scholar
• Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56:1113–1132.
   PubMed Web of Science ®Google Scholar
• Li W, Ma D, Liu M, et al. Association between metabolic syndrome and risk of stroke: a meta-analysis of cohort studies. Cerebrovasc Dis. 2008;25:539–547.
   PubMed Web of Science ®Google Scholar
• Novo S, Peritore A, Guarneri FP, et al. Metabolic syndrome (MetS) predicts cardio and cerebrovascular events in a twenty years follow-up. A prospective study. Atherosclerosis. 2012;223:468–472.
   PubMed Web of Science ®Google Scholar
• Wu SH, Liu Z, Ho SC, et al. Metabolic syndrome and all-cause mortality: a meta-analysis of prospective cohort studies. Eur J Epidemiol. 2010;25:375–384.
   PubMed Web of Science ®Google Scholar
• Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007;49:403–414.
   PubMed Web of Science ®Google Scholar
• Ju SY, Lee JY, Kim DH. Association of metabolic syndrome and its components with all-cause and cardiovascular mortality in the elderly: A meta-analysis of prospective cohort studies. Medicine (Baltimore). 2017;96:e8491.
   PubMed Web of Science ®Google Scholar
• Hess PL, Al-Khalidi HR, Friedman DJ, et al. The Metabolic syndrome and risk of sudden cardiac death: the atherosclerosis risk in communities study. J Am Heart Assoc. 2017;6:e006103.
   PubMed Web of Science ®Google Scholar
• Ma X, Zhu S. Metabolic syndrome in the prevention of cardiovascular diseases and diabetes–still a matter of debate? Eur J Clin Nutr. 2013;67:518–521.
   PubMed Web of Science ®Google Scholar
• Yen YF, Hu HY, Lin IF, et al. Associations of Metabolic Syndrome and its Components With Mortality in the Elderly: A Cohort Study of 73,547 Taiwanese Adults. Medicine (Baltimore). 2015;94:e956.
   PubMed Web of Science ®Google Scholar
• van Herpt TT, Dehghan A, van Hoek M, et al. The clinical value of metabolic syndrome and risks of cardiometabolic events and mortality in the elderly: the Rotterdam study. Cardiovasc Diabetol. 2016 Apr;27(15):69.
   Google Scholar
• Chen Q, Zhang Y, Ding D, et al. Metabolic syndrome and its individual components with mortality among patients with coronary heart disease. Int J Cardiol. 2016;224:8–14.
   PubMed Web of Science ®Google Scholar
• Grandl G, Wolfrum C. Hemostasis, endothelial stress, inflammation, and the metabolic syndrome. Semin Immunopathol. 2018;40:215–224.
   PubMed Web of Science ®Google Scholar
• Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest. 2011;121:2111–2117.
   PubMed Web of Science ®Google Scholar
• Abella V, Scotece M, Conde J, et al. Adipokines, metabolic syndrome and rheumatic diseases. J Immunol Res. 2014;2014:343746.
   PubMed Web of Science ®Google Scholar
• Medina G, Vera-Lastra O, Peralta-Amaro AL, et al. Metabolic syndrome, autoimmunity and rheumatic diseases. Pharmacol Res. 2018 Jul;133:277–288.
   PubMed Web of Science ®Google Scholar
• Frühbeck G, Catalán V, Rodríguez A, et al. Involvement of the leptin-adiponectin axis in inflammation and oxidative stress in the metabolic syndrome. Sci Rep. 2017;7:6619.
   PubMed Web of Science ®Google Scholar
• McCracken E, Monaghan M, Sreenivasan S. Pathophysiology of the metabolic syndrome. Clin Dermatol. 2018;36:14–20.
   PubMed Web of Science ®Google Scholar
• Van Raemdonck K, Umar S, Szekanecz Z, et al. Impact of obesity on autoimmune arthritis and its cardiovascular complications. Autoimmun Rev. 2018;17:821–835.
   PubMed Web of Science ®Google Scholar
• Mok CC. Systemic lupus erythematosus: what should family physicians know in 2018? Hong Kong Med J. 2018;24:501–511.
   PubMed Web of Science ®Google Scholar
• Mok CC. The Jakinibs in systemic lupus erythematosus: progress and prospects. Expert Opin Investig Drugs. 2019;28:85–92.
   PubMed Web of Science ®Google Scholar
• Mok CC. Accelerated atherosclerosis, arterial thromboembolism, and preventive strategies in systemic lupus erythematosus. Scand J Rheumatol. 2006;35:85–95.
   PubMed Web of Science ®Google Scholar
• Croca S, Rahman A. Atherosclerosis in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2017;31:364–372.
   PubMed Web of Science ®Google Scholar
• Sun C, Qin W, Zhang Y-H, et al. Prevalence and risk of metabolic syndrome in patients with systemic lupus erythematosus: A meta-analysis. Int J Rheum Dis. 2017;20:917–928.
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539–553.
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421.
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome–a new worldwide definition. Lancet. 2005;366:1059–1062.
   PubMed Web of Science ®Google Scholar
• Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999;16:442–443.
   PubMed Web of Science ®Google Scholar
• Bloomgarden ZT. American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome: 25-26 August 2002, Washington, DC. Diabetes Care. 2003;26:1297–1303.
   PubMed Web of Science ®Google Scholar
• Alberti KG, Eckel RH, Grundy SMZ, et al. International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Circulation. 2009;120:1640–1645.
   PubMed Web of Science ®Google Scholar
• Heng D, Ma S, Lee JJ, et al. Modification of the NCEP ATP III definitions of the metabolic syndrome for use in Asians identifies individuals at risk of ischemic heart disease. Atherosclerosis. 2006;186:367–373.
   PubMed Web of Science ®Google Scholar
• Katz P, Gregorich S, Yazdany J, et al. Obesity and its measurement in a community-based sample of women with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2011;63:261–268.
   PubMed Web of Science ®Google Scholar
• Versini M, Tiosano S, Comaneshter D, et al. Smoking and obesity in systemic lupus erythematosus: a cross-sectional study. Eur J Clin Invest. 2017;47:422–427.
   PubMed Web of Science ®Google Scholar
• Patterson SL, Schmajuk G, Jafri K, et al. Obesity is independently associated with worse patient-reported outcomes in women with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2019;71:126–133.
   PubMed Web of Science ®Google Scholar
• Tedeschi SK, Barbhaiya M, Malspeis S, et al. Obesity and the risk of systemic lupus erythematosus among women in the Nurses’ Health Studies. Semin Arthritis Rheum. 2017;47:376–383.
   PubMed Web of Science ®Google Scholar
• Cozier YC, Barbhaiya M, Castro-Webb N, et al. A prospective study of obesity and risk of systemic lupus erythematosus (SLE) among Black women. Semin Arthritis Rheum. 2018;S0049-0172(18)30425–6.
   PubMed Web of Science ®Google Scholar
• Katz P, Julian L, Tonner MC, et al. Physical activity, obesity, and cognitive impairment among women with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012;64:502–510.
   PubMed Web of Science ®Google Scholar
• Oeser A, Chung CP, Asanuma Y, et al. Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. Arthritis Rheum. 2005;52:3651–3659.
   PubMed Web of Science ®Google Scholar
• Mok CC, Ying SK, To CH, et al. Bone mineral density and body composition in men with systemic lupus erythematosus: a case control study. Bone. 2008;43:327–331.
   PubMed Web of Science ®Google Scholar
• Szabó MZ, Szodoray P, Kiss E. Dyslipidemia in systemic lupus erythematosus. Immunol Res. 2017;65:543–550.
   PubMed Web of Science ®Google Scholar
• Tselios K, Koumaras C, Gladman D, et al. Dyslipidemia in systemic lupus erythematosus: just another comorbidity?. Semin Arthritis Rheum. 2016;45:604–610.
   PubMed Web of Science ®Google Scholar
• Borba EF, Bonfá E. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus. 1997;6:533–539.
   PubMed Web of Science ®Google Scholar
• Tyrrell PN, Beyene J, Benseler SM, et al. Predictors of lipid abnormalities in children with new-onset systemic lupus erythematosus. J Rheumatol. 2007;34:2112–2119.
   PubMed Web of Science ®Google Scholar
• Al-Herz A, Ensworth S, Shojania K, et al. Cardiovascular risk factor screening in systemic lupus erythematosus. J Rheumatol. 2003;30:493–496.
   PubMed Web of Science ®Google Scholar
• Sabio JM, Vargas-Hitos JA, Navarrete-Navarrete N, et al. Prevalence of and factors associated with hypertension in young and old women with systemic lupus erythematosus. J Rheumatol. 2011;38:1026–1032.
   PubMed Web of Science ®Google Scholar
• Shaharir SS, Mustafar R, Mohd R, et al. Persistent hypertension in lupus nephritis and the associated risk factors. Clin Rheumatol. 2015;34:93–97.
   PubMed Web of Science ®Google Scholar
• Wolf VL, Ryan MJ. Autoimmune Disease-Associated Hypertension. Curr Hypertens Rep. 2019;21:10.
   PubMed Web of Science ®Google Scholar
• Sabio JM, Vargas-Hitos JA, Martínez Bordonado J, et al. Association between non-dipper hypertension and vitamin D deficiency in women with systemic lupus erythematosus. Clin Exp Rheumatol. 2019;37:286–292.
   PubMed Web of Science ®Google Scholar
• Ramirez LA, Sullivan JC. Sex Differences in Hypertension: where We Have Been and Where We Are Going. Am J Hypertens. 2018;31:1247–1254.
   PubMed Web of Science ®Google Scholar
• Bravo PE, Morse S, Borne DM, et al. Leptin and hypertension in obesity. Vasc Health Risk Manag. 2006;2:163–169.
   PubMedGoogle Scholar
• Li HM, Zhang TP, Leng RX, et al. Emerging role of adipokines in systemic lupus erythematosus. Immunol Res. 2016;64:820–830.
   PubMed Web of Science ®Google Scholar
• Ryan MJ, McLemore GR Jr, St H. Insulin resistance and obesity in a mouse model of systemic lupus erythematosus. Hypertension. 2006;48:988–993.
   PubMed Web of Science ®Google Scholar
• Toller-Kawahisa JE, Canicoba N, Venancio V, et al. Systemic lupus erythematosus onset in lupus-prone B6.MRL/lpr mice Is influenced by weight gain and Is preceded by an increase in neutrophil oxidative burst activity. Free Radic Biol Med. 2015;86:362–373.
   PubMed Web of Science ®Google Scholar
• El Magadmi M, Ahmad Y, Turkie W, et al. Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J Rheumatol. 2006;33:50–56.
   PubMed Web of Science ®Google Scholar
• Chung CP, Oeser A, Solus JF, et al. Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum. 2008;58:2105–2112.
   PubMed Web of Science ®Google Scholar
• Miyake CNH, Gualano B, Dantas WS, et al. Increased insulin resistance and glucagon levels in mild/inactive systemic lupus erythematosus patients despite normal glucose tolerance. Arthritis Care Res (Hoboken). 2018;70:114–124.
   PubMed Web of Science ®Google Scholar
• Sánchez-Pérez H, Tejera-Segura B, de Vera-González A, et al. Insulin resistance in systemic lupus erythematosus patients: contributing factors and relationship with subclinical atherosclerosis. Clin Exp Rheumatol. 2017;35:885–892.
   PubMed Web of Science ®Google Scholar
• Sabio JM, Vargas-Hitos JA, Martinez-Bordonado J, et al. Association between low 25-hydroxyvitamin D, insulin resistance and arterial stiffness in nondiabetic women with systemic lupus erythematosus. Lupus. 2015;24:155–163.
   PubMed Web of Science ®Google Scholar
• Lozovoy MA, Simão AN, Oliveira SR, et al. Relationship between iron metabolism, oxidative stress, and insulin resistance in patients with systemic lupus erythematosus. Scand J Rheumatol. 2013;42:303–310.
   PubMed Web of Science ®Google Scholar
• Parker B, Bruce I. SLE and metabolic syndrome. Lupus. 2013;22:1259–1266.
   PubMed Web of Science ®Google Scholar
• Parker B, Ahmad Y, Shelmerdine J, et al. An analysis of the metabolic syndrome phenotype in systemic lupus erythematosus. Lupus. 2011;20:1459–1465.
   PubMed Web of Science ®Google Scholar
• Sabio JM, Zamora-Pasadas M, Jime´ nez-Ja´ Imez J, et al. Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain. Lupus. 2008;17:849–859.
   PubMed Web of Science ®Google Scholar
• Hallajzadeh J, Khoramdad M, Izadi N, et al. The association between metabolic syndrome and its components with systemic lupus erythematosus: a comprehensive systematic review and meta-analysis of observational studies. Lupus. 2018;1:961203317751047.
   Google Scholar
• Chung CP, Avalos I, Oeser A, et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis. 2007;66:208–214.
   PubMed Web of Science ®Google Scholar
• Bellomio V, Spindler A, Lucero E, et al. SLE study group of the argentinean society of rheumatology. Metabolic syndrome in Argentinean patients with systemic lupus erythematosus. Lupus. 2009;18:1019–1025.
   PubMed Web of Science ®Google Scholar
• Negrón AM, Molina MJ, Mayor AM, et al. Factors associated with metabolic syndrome in patients with systemic lupus erythematosus from Puerto Rico. Lupus. 2008;17:348–354.
   PubMed Web of Science ®Google Scholar
• Mok CC, Poon WL, Lai JP, et al. Metabolic syndrome, endothelial injury, and subclinical atherosclerosis in patients with systemic lupus erythematosus. Scand J Rheumatol. 2010;39:42–49.
   PubMed Web of Science ®Google Scholar
• Parker B, Urowitz MB, Gladman DD, et al. Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis. 2015;74:1530–1536.
   PubMed Web of Science ®Google Scholar
• Muniz LF, Pereira RM, Silva TF, et al. Impact of therapy on metabolic syndrome in young adult premenopausal female lupus patients: beneficial effect of antimalarials. Arthritis Care Res (Hoboken). 2015;67:1255–1262.
   PubMed Web of Science ®Google Scholar
• Medeiros MM, Xavier de Oliveira ÍM, Ribeiro ÁT. Prevalence of metabolic syndrome in a cohort of systemic lupus erythematosus patients from Northeastern Brazil: association with disease activity, nephritis, smoking, and age. Rheumatol Int. 2016;36:117–124.
   PubMed Web of Science ®Google Scholar
• Wang LM, Zheng ZH, Li TF, et al. 25-hydroxyvitamin D is associated with metabolic syndrome among premenopausal women with systemic lupus erythematosus in China. Lupus. 2017;26:403–409.
   PubMed Web of Science ®Google Scholar
• Demir S, Erten G, Artım-Esen B, et al. Increased serum leptin levels are associated with metabolic syndrome and carotid intima media thickness in premenopausal systemic lupus erythematosus patients without clinical atherosclerotic vascular events. Lupus. 2018;27:1509–1516.
   PubMed Web of Science ®Google Scholar
• Mobini M, Niksolat F, Mohammadpour RA, et al. Metabolic syndrome in patients with systemic lupus erythematosus: association with disease activity, disease damage and age. Int J Rheum Dis. 2018;21:1023–1030.
   PubMed Web of Science ®Google Scholar
• Fatemi A, Ghanbarian A, Sayedbonakdar Z, et al. Metabolic syndrome in Iranian patients with systemic lupus erythematosus and its determinants. Clin Rheumatol. 2018;37:1521–1528.
   PubMed Web of Science ®Google Scholar
• Mok CC, Tse SM, Chan KL, et al. Effect of the metabolic syndrome on organ damage and mortality in patients with systemic lupus erythematosus: a longitudinal analysis. Clin Exp Rheumatol. 2018;36:389–395.
   PubMed Web of Science ®Google Scholar
• Da Rosa Franchi Santos LF, Stadtlober NP, Costa Dall’Aqua LG, et al. Increased adhesion molecule levels in systemic lupus erythematosus: relationships with severity of illness, autoimmunity, metabolic syndrome and cortisol levels. Lupus. 2018;27:380–388.
   PubMed Web of Science ®Google Scholar
• Conti F, Ceccarelli F, Perricone C, et al. The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort. Lupus. 2016 Jun;25(7):719–726.
   PubMed Web of Science ®Google Scholar
• Tarr T, Papp G, Nagy N, et al. Chronic high-dose glucocorticoid therapy triggers the development of chronic organ damage and worsens disease outcome in systemic lupus erythematosus. Clin Rheumatol. 2017 Feb;36(2):327–333.
   PubMed Web of Science ®Google Scholar
• Chen HL, Shen LJ, Hsu PN, et al. Cumulative burden of glucocorticoid-related adverse events in patients with systemic lupus erythematosus: findings from a 12-year longitudinal study. J Rheumatol. 2018;45:83–89.
   PubMed Web of Science ®Google Scholar
• Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus. 2000;9(3):170–175.
   PubMed Web of Science ®Google Scholar
• Magder LS, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol. 2012;176:708–719.
   PubMed Web of Science ®Google Scholar
• Sabio JM, Vargas-Hitos J, Zamora-Pasadas M, et al. Metabolic syndrome is associated with increased arterial stiffness and biomarkers of subclinical atherosclerosis in patients with systemic lupus erythematosus. J Rheumatol. 2009;36:2204–2211.
   PubMed Web of Science ®Google Scholar
• Valero-Gonzalez S, Castejon R, Jimenez-Ortiz C, et al. Increased arterial stiffness is independently associated with metabolic syndrome and damage index in systemic lupus erythematosus patients. Scand J Rheumatol. 2014;43:54–58.
   PubMed Web of Science ®Google Scholar
• Castejon R, Jimenez-Ortiz C, Rosado S, et al. Metabolic syndrome is associated with decreased circulating endothelial progenitor cells and increased arterial stiffness in systemic lupus erythematosus. Lupus. 2016;25:129–136.
   PubMed Web of Science ®Google Scholar
• Gheita TA, Raafat HA, Sayed S, et al. Metabolic syndrome and insulin resistance comorbidity in systemic lupus erythematosus. Effect on carotid intima-media thickness. Z Rheumatol. 2013;72:172–177.
   PubMed Web of Science ®Google Scholar
• Zhang M, Qi C, Cao L, et al. Metabolic syndrome is correlated with carotid atherosclerosis in patients with lupus nephritis. Am J Med Sci. 2014;348:486–491.
   PubMed Web of Science ®Google Scholar
• García-Villegas EA, Lerman-Garber I, Flores-Suárez LF, et al. Prognostic value of metabolic syndrome for the development of cardiovascular disease in a cohort of premenopausal women with systemic lupus erythematosus. Med Clin (Barc). 2015;144:289–296.
   PubMed Web of Science ®Google Scholar
• Demir S, Artim-Esen B, Şahinkaya Y, et al. Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients. Lupus. 2016;25:177–184.
   PubMed Web of Science ®Google Scholar
• Margiotta DPE, Basta F, Dolcini G, et al. The relation between, metabolic syndrome and quality of life in patients with Systemic Lupus Erythematosus. PLoS One. 2017;12:e0187645.
   PubMed Web of Science ®Google Scholar
• Lee JW, Kang JH, Lee KE, et al. Effects of risk factors for and components of metabolic syndrome on the quality of life of patients with systemic lupus erythematosus: a structural equation modeling approach. Qual Life Res. 2018;27:105–113.
   PubMed Web of Science ®Google Scholar
• Prasad GV. Metabolic syndrome and chronic kidney disease: current status and future directions. World J Nephrol. 2014;3:210–219.
   PubMedGoogle Scholar
• Thomas G1, Sehgal AR, Kashyap SR, et al. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2011;6:2364–2373.
   PubMed Web of Science ®Google Scholar
• Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. Adults Ann Intern Med. 2004;140:167–174.
   PubMed Web of Science ®Google Scholar
• Pons-Estel GJ, Andreoli L, Scanzi F, et al. The antiphospholipid syndrome in patients with systemic lupus erythematosus. J Autoimmun. 2017;76:10–20.
   PubMed Web of Science ®Google Scholar
• Rodrigues CE, Bonfá E, Caleiro MT, et al. Association of arterial events with the coexistence of metabolic syndrome and primary antiphospholipid syndrome. Arthritis Care Res (Hoboken). 2012;64:1576–1583.
   PubMed Web of Science ®Google Scholar
• Medina G, Gutiérrez-Moreno AL, Vera-Lastra O, et al. Prevalence of metabolic syndrome in primary antiphospholipid syndrome patients. Autoimmun Rev. 2011;10:214–217.
   PubMed Web of Science ®Google Scholar
• Rodrigues CE, Vendramini MB, Bueno C, et al. Adipocytokines in primary antiphospholipid syndrome: potential markers of low-grade inflammation, insulin resistance and metabolic syndrome. Clin Exp Rheumatol. 2012;30:871–878.
   PubMed Web of Science ®Google Scholar
• Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014;2014:943162.
   PubMedGoogle Scholar
• Bell-Anderson KS. Adipokines: linking obesity and cardiovascular disease. Expert Rev Endocrinol Metab. 2008;3:61–73.
   PubMedGoogle Scholar
• Zhu Q, Scherer PE. Immunologic and endocrine functions of adipose tissue: implications for kidney disease. Nat Rev Nephrol. 2018;14:105–120.
   PubMed Web of Science ®Google Scholar
• Bao P, Liu G, Wei Y. Association between IL-6 and related risk factors of metabolic syndrome and cardiovascular disease in young rats. Int J Clin Exp Med. 2015;8:13491–13499.
   PubMed Web of Science ®Google Scholar
• McKellar GE, McCarey DW, Sattar N, et al. Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol. 2009;6:410–417.
   PubMed Web of Science ®Google Scholar
• Kern PA, Ranganathan S, Li C, et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001;280:E745–E751.
   PubMed Web of Science ®Google Scholar
• Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol. 2006;26:2200–2207.
   PubMed Web of Science ®Google Scholar
• Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004;114:1752–1761.
   PubMed Web of Science ®Google Scholar
• Chung CP, Long AG, Solus JF, et al. Adipocytokines in systemic lupus erythematosus: relationship to inflammation, insulin resistance and coronary atherosclerosis. Lupus. 2009;18:799–806.
   PubMed Web of Science ®Google Scholar
• Vadacca M, Margiotta D, Rigon A, et al. Adipokines and systemic lupus erythematosus: relationship with metabolic syndrome and cardiovascular disease risk factors. J Rheumatol. 2009;36:295–297.
   PubMed Web of Science ®Google Scholar
• McMahon M, Skaggs BJ, Sahakian L, et al. High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. Ann Rheum Dis. 2011;70:1619–1624.
   PubMed Web of Science ®Google Scholar
• Wang X, Qiao Y, Yang L, et al. Leptin levels in patients with systemic lupus erythematosus inversely correlate with regulatory T cell frequency. Lupus. 2017;26:1401–1406.
   PubMed Web of Science ®Google Scholar
• De Sanctis JB, Zabaleta M, Bianco NE, et al. Serum adipokine levels in patients with systemic lupus erythematosus. Autoimmunity. 2009;42:272–274.
   PubMed Web of Science ®Google Scholar
• Wisłowska M, Rok M, Stepień K, et al. Serum leptin in systemic lupus erythematosus. Rheumatol Int. 2008;28:467–473.
   PubMed Web of Science ®Google Scholar
• Li HM, Zhang TP, Leng RX, et al. Plasma/Serum leptin levels in patients with systemic lupus erythematosus: a meta-analysis. Arch Med Res. 2015;46:551–556.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Mantzoros C, Mikhailidis DP. Adiponectin, lipids and atherosclerosis. Curr Opin Lipidol. 2017;28:347–354.
   PubMed Web of Science ®Google Scholar
• Matsuzawa Y, Funahashi T, Kihara S, et al. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004;24:29–33.
   PubMed Web of Science ®Google Scholar
• Srikanthan K, Feyh A, Visweshwar H, et al. Systematic review of metabolic syndrome biomarkers: a panel for early detection, management, and risk stratification in the West Virginian population. Int J Med Sci. 2016;13:25–38.
   PubMed Web of Science ®Google Scholar
• Ryo M, Nakamura T, Kihara S, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J. 2004;68:975–981.
   PubMed Web of Science ®Google Scholar
• Dini AA, Wang P, Ye D-Q. Serum Adiponectin Levels in Patients With Systemic Lupus Erythematosus: A Meta-analysis. J Clin Rheumatol. 2017;23:361–367.
   PubMed Web of Science ®Google Scholar
• Huang Q, Tao -S-S, Zhang Y-J, et al. Serum resistin levels in patients with rheumatoid arthritis and systemic lupus erythematosus: a meta-analysis. Clin Rheumatol. 2015;34:1713–1720.
   PubMed Web of Science ®Google Scholar
• Chougule D, Nadkar M, Venkataraman K, et al. Adipokine interactions promote the pathogenesis of systemic lupus erythematosus. Cytokine. 2018;111:20–27.
   PubMed Web of Science ®Google Scholar
• Dimitroulas T, Sandoo A, Kitas GD. Asymmetric dimethylarginine as a surrogate marker of endothelial dysfunction and cardiovascular risk in patients with systemic rheumatic diseases. Int J Mol Sci. 2012;13:12315–12335.
   PubMed Web of Science ®Google Scholar
• Siervo M, Bluck LJ. In vivo nitric oxide synthesis, insulin sensitivity, and asymmetric dimethylarginine in obese subjects without and with metabolic syndrome. Metabolism. 2012;61:680–688.
   PubMed Web of Science ®Google Scholar
• Perna M, Roman MJ, Alpert DR, et al. Relationship of asymmetric dimethylarginine and homocysteine to vascular aging in systemic lupus erythematosus patients. Arthritis Rheum. 2010;62:1718–1722.
   PubMedGoogle Scholar
• Kiani AN, Mahoney JA, Petri M. Asymmetric dimethylarginine is a marker of poor prognosis and coronary calcium in systemic lupus erythematosus. J Rheumatol. 2007;34:1502–1505.
   PubMed Web of Science ®Google Scholar
• Torres S, Fabersani E, Marquez A, et al. Adipose tissue inflammation and metabolic syndrome. The proactive role of probiotics. Eur J Nutr. 2018 Jul 24. DOI:10.1007/s00394-018-1790-2 [Epub ahead of print].
   Web of Science ®Google Scholar
• de Oliveira GLV, Leite AZ, Higuchi BS, et al. Intestinal dysbiosis and probiotic applications in autoimmune diseases. Immunology. 2017;152:1–12.
   PubMed Web of Science ®Google Scholar
• Katz-Agranov N, Zandman-Goddard G. The microbiome and systemic lupus erythematosus. Immunol Res. 2017;65:432–437.
   PubMed Web of Science ®Google Scholar
• Yamaoka K, Tango T. Effects of lifestyle modification on metabolic syndrome: a systematic review and meta-analysis. BMC Med. 2012;10:138.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2018 Nov 8;2018:S0735-1097(18)39034-X. [Epub ahead of print].
   Google Scholar
• Rask Larsen J, Dima L, Correll CU, et al. The pharmacological management of metabolic syndrome. Expert Rev Clin Pharmacol. 2018;11:397–410.
   PubMed Web of Science ®Google Scholar
• Okopień B, Bułdak Ł, Bołdys A. Benefits and risks of the treatment with fibrates–a comprehensive summary. Expert Rev Clin Pharmacol. 2018;11:1099–1112.
   PubMed Web of Science ®Google Scholar
• Ladeiras-Lopes R, Fontes-Carvalho R, Bettencourt N, et al. Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease. Expert Opin Ther Targets. 2015;19:869–877.
   PubMed Web of Science ®Google Scholar
• Varjabedian L, Bourji M, Pourafkari L, et al. Cardioprotection by Metformin: beneficial Effects Beyond Glucose Reduction. Am J Cardiovasc Drugs. 2018;18:181–193.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Investigators. Liraglutide and Cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
   PubMed Web of Science ®Google Scholar
• Floris A, Piga M, Mangoni AA, et al. Protective effects of hydroxychloroquine against accelerated atherosclerosis in systemic lupus erythematosus. Mediators Inflamm. 2018;2018:3424136. eCollection 2018.
   PubMed Web of Science ®Google Scholar
• Rempenault C, Combe B, Barnetche T, et al. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2018;77:98–103.
   PubMed Web of Science ®Google Scholar
• Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71:1771–1782.
   PubMed Web of Science ®Google Scholar
• Fanouriakis A, Kostopoulou M, Alunno A, et al. update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019 Mar 29;2019:annrheumdis-2019–215089. [Epub ahead of print].
   Google Scholar